CANCER LEADERSHIP COUNCIL
    
    
    
    CLC
              comments on alternative payment systems 
      
              (November 17, 2015)
      
    
        
       November
        17, 2015
        
        
        
        Andy Slavitt
        Acting Administrator
        
Centers for Medicare & Medicaid Services
        Department of Health and Human Services
        Hubert H. Humphrey Building
        200 Independence Avenue, SW
        Washington, DC  20201
      
     RE:   
         CMS-3321-NC, Request for Information Regarding
        Implementation of the Merit-Based Incentive Payment System,
        Promotion of Alternative Payment Models, and Incentive Payments
        for Participation in Eligible Alternative Payment Models
     
        Dear Mr. Slavitt:
        
        
The undersigned organizations represent cancer patients,
        physicians, and researchers who support health care payment and
        delivery reforms that will foster patient-centered cancer
        care.  We appreciate the opportunity to respond to the
        Request for Information regarding the Merit-Based Incentive
        Payment System and Alternative Payment Models.  We look
        forward to ongoing interaction with the Centers for Medicare and
        Medicaid Services (CMS) during the process of physician payment
        transformation that is outlined in the Medicare Access and CHIP
        Reauthorization Act of 2015 (MACRA). 
        
        The comments below focus on two of the performance categories in
        the Merit-Based Incentive Payment System (MIPA) and recommend an
        Alternative Payment System that would ensure the delivery of
        high-quality survivorship care to Medicare beneficiaries who are
        cancer survivors.    We provide specific feedback
        on the measures and activities related to two of the four
        performance categories under the MIPS.   
        
        Resource Use Performance Category
        
        MACRA requires the Secretary to evaluate costs – or resource use
        – based on a composite of appropriate measures of
        costs.   The methodology for evaluating resource use
        is defined in MACRA, and the experience of CMS in the
        Value-Based Payment Modifier (VM) system is 
        
        assumed to be relevant to this evaluation.  The Request for
        Information seeks comment on the development of a resource use
        measure that, in addition to measuring overall costs of care,
        would evaluate harmful or over-used services, including those
        identified in the Choosing Wisely initiative.  
        
        Instead of a resource measure that would focus only on potential
        over-utilization, we urge development of a resource measure for
        cancer care delivery that would focus on appropriate, or
        targeted, utilization of services.  Cancer therapies are
        increasingly targeted according to the molecular profile of a
        patient’s cancer.  Not all cancer treatments are targeted
        medicines, of course.  However, for those medicines that
        developed for specific targets, there are too many failures
        related to their delivery. 
        
        If patients do not undergo proper molecular diagnosis, they may
        not receive medicines that would provide benefit.  On the
        other hand, patients who will not benefit from targeted
        therapies may receive them inappropriately because they are not
        properly diagnosed.  In this case, there is
        over-utilization of the targeted therapy, but mostly
        importantly, the patient is not receiving the treatment best for
        him or her.  These delivery failures result in improper
        utilization – both overutilization and underutilization. 
        We urge that a measure for proper molecular diagnosis and
        subsequent use of targeted cancer therapies be incorporated in
        the resource use performance category.   Such an
        effort is necessary for proper resource utilization, including
        of new targeted cancer therapies, and to ensure that patients
        receive the right treatment at the right time.  We
        understand that diagnostic tests are not available for all
        therapies and that not all cancer therapies are
        “targeted.”  However, accurate diagnosis, including
        molecular diagnosis where appropriate, should guide treatment
        decisions.  
        
        Clinical Practice Improvement Activities Performance
            Category
        
        The term “clinical practice improvement” is defined in the
        Social Security Act, as amended by MACRA, as “an activity that
        relevant eligible professional organizations and other relevant
        stakeholders identify as improving clinical practice or care
        delivery and that the Secretary determines, when effectively
        executed, is likely to result in improved outcomes.” 
        Moreover, the Act specifies that the measures and activities for
        the clinical practice improvement activities performance
        category must include at least these efforts:  expanded
        practice access, population management, care coordination,
        beneficiary engagement, patient safety and practice assessment,
        and participation in an alternative practice model. 
        
        Our comments focus on defining a subcategory of clinical
        practice improvement activity, which might most logically be
        classified under the “care coordination” performance
        activity.  We propose a treatment planning and coordination
        activity subcategory that would include these elements:  1)
        shared decision-making that considers treatment goals and
        outlines all elements of active treatment and symptom management
        in a written plan, 2) coordination of all elements of
        multi-disciplinary cancer care, and 3) appropriate management of
        the side effects of treatment and symptoms of
        cancer.    
        
        Cancer care that is planned according to the patient’s
        preferences and that coordinates active treatment and symptom
        management from the beginning of treatment holds the promise of
        boosting patient satisfaction with care, improving outcomes, and
        enhancing the appropriate utilization of cancer care resources.1  
        If a practice undertakes this sort of treatment planning and
        coordination, the process of practice transformation will be
        accelerated, quality of care and patient satisfaction will be
        improved, and appropriate resource utilization will be
        encouraged.
        
        The “subcategory activity” of treatment planning and
        coordination can be reported by cancer care providers through a
        qualified registry or electronic health record.  We also
        propose that a Consumer Assessment of Healthcare Providers and
        Systems (CAHPS) item set focusing on treatment planning and
        coordination be developed and utilized as part of the reporting
        and assessment of clinical practice improvement activities and
        specifically treatment planning and coordination.  There
        exists a CAHPS item set that gathers information on patient
        experience in a patient-centered medical home; a modification of
        that item set might be useful in assessing cancer care provider
        implementation of the activities of treatment planning and
        coordination.  
        
        The Request for Information seeks comment on the benchmark for
        assessing performance on clinical practice improvement
        activities.  We urge CMS to develop a MIPS performance
        benchmark for clinical practice improvement activities that will
        not penalize those oncology practices that have already made
        progress toward practice transformation through clinical
        practice improvement.  These would include oncology
        practices that are already testing the patient-centered medical
        home concept and others that are undertaking practice
        improvements.  These practices would include certain
        participants in the American Society of Clinical Oncology
        Quality Oncology Practice Initiative.  
        
        An Alternative Payment Model for Cancer Survivorship Care
        
        Congress anticipated that MACRA would encourage the development
        of alternative payment models by medical professionals, their
        professional societies, and health systems.  In fact, the
        law describes the new payment models as “physician-focused,” and
        requires that they be evaluated for implementation by the
        “Physician-focused Payment Model Technical Advisory
        Committee.”  We propose a patient-focused payment and care
        model that could be implemented under the framework of a
        “physician-focused” system.
        
        We recommend an alternative payment system for the delivery of
        comprehensive cancer survivorship care.  Individuals who
        have been diagnosed with cancer and received treatment that
        might include surgery, radiation, and chemotherapy are often
        “lost in transition” as they move from active treatment to
        long-term survivorship.2
        
        In a 2006 report on the problems of cancer survivors, the
        National Cancer Policy Board of the Institute of Medicine
        identified the essential components of survivorship care. 
        These are:
      
    
      - Prevention of
            recurrent and new cancers and the prevention of other late
            effects;
 
      - Surveillance
            for cancer spread, recurrence, and second cancers, as well
            as the assessment of medical and psychosocial late effects;
 
      - Intervention
            for the consequences of cancer and its treatment. 
            These consequences might include lymphedema and sexual
            dysfunction, pain, fatigue, depression, psychological
            distress, and concerns related to employment, insurance, and
            disability; and
 
      - Coordination
            between primary care providers and specialists to ensure
            that survivors’ health needs, as described above, are
            addressed.3
 
    
    An alternative
        payment system including providers caring for cancer survivors
        holds great promise for addressing the serious and complex
        chronic health care needs of many cancer survivors and fairly
        compensating cancer care professionals providing this complex
        care.  The need for a system of this sort is clear. 
        There will be a 30% increase in the number of cancer survivors
        by 2022 and a 45% increase in cancer incidence by 2030. 
        Approximately 53% of cancer diagnoses were in individuals 65 and
        older in 2012, and 59% of cancer survivors were 65 years or
        older in 2012.4
    
        The burden of cancer and cancer survivorship on individuals,
        families, and the nation is significant.  Medicare
        beneficiaries and the Medicare program bear significant
        financial responsibility for the cancer care system simply
        because of the incidence of cancer and the number of cancer
        survivors in this population.  An alternative payment
        system might focus initially on Medicare beneficiaries who are
        cancer survivors and be expanded to other populations of cancer
        survivors.  
        
        We anticipate challenges associated with the development of an
        alternative payment system that would focus on a specific
        population, but its potential benefits argue for its
        consideration as a range of alternative payment systems are
        developed and implemented.  We encourage CMS to entertain
        proposals for cancer survivorship care and to take an additional
        step by providing guidance that would address ways to combine a
        patient-centered payment system with the physician-focused
        payment reform structure. 
        
        We appreciate the opportunity to offer comments on MIPS and on
        alternative payment systems and look forward to additional
        discussion with CMS about ensuring a patient focus in these
        payment reform efforts. 
        
        Sincerely,
        
        Cancer Leadership Council
        
        American Society for Radiation Oncology 
        CancerCare
        Cancer Support Community
        The Children's Cause for Cancer Advocacy
        Fight Colorectal Cancer
        International Myeloma Foundation
        The Leukemia & Lymphoma Society
        LIVESTRONG Foundation
        Lymphoma Research Foundation
        Multiple Myeloma Research Foundation
        National Coalition for Cancer Survivorship
        National Patient Advocate Foundation
        Ovarian Cancer National Alliance
        Pancreatic Cancer Action Network
        Prevent Cancer Foundation
        Susan G. Komen
        Us TOO International Prostate Cancer Education and Support
        Network
      
      
      1 Temel JS, Greer JA, Muzikansky A, et al. 
      Early Palliative Care for Patients with Metastatic Non-Small-Cell
      Lung Cancer.  N Engl J Med.  August 19, 2010.  
      2  Hewitt M, Greenfield S, and Stovall E. 
      From Cancer Patient to Cancer Survivor: Lost in Transition,
      National Cancer Policy Board of Institute of Medicine, 2006.
       
      3  Hewitt M, et al.  From Cancer Patient to
      Cancer Survivor.  2006. 
      4  Levitt LA, Balogh EP, Nass SJ, and Ganz
      PA.  Delivering High-Quality Cancer Care: Charting a New
      Course for a System in Crisis.  Institute of Medicine, 2013.